Home Merck Announces Third-Quarter 2015 Financial Results
 

Keywords :   


Merck Announces Third-Quarter 2015 Financial Results

2015-10-27 11:45:00| Merck.com - Corporate News

Dateline City: KENILWORTH, N.J. Increased Non-GAAP EPS by 7 Percent to $0.96; GAAP EPS of $0.64 Raised 2015 Full-Year Non-GAAP EPS Target to a Range of $3.55 $3.60 and GAAP EPS Target to a Range of $1.64 $1.74 Worldwide Sales Were $10.1 Billion, a Decrease of 5 Percent; Excluding the Impact of Foreign Exchange, Acquisitions and Divestitures, Worldwide Sales Grew 4 Percent Advanced KEYTRUDA Program FDA Approved sBLA for the Treatment of Previously Treated Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1 In KEYNOTE-010 Study KEYTRUDA Showed Superior Overall Survival Compared to Chemotherapy in Patients with Previously Treated Advanced NSCLC Whose Tumors Express PD-L1 Third-Quarter Sales Were Approximately $160 million KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced financial results for the third quarter of 2015. Language: English Contact: MerckMedia:Lainie Keller, 908-236-5036Steven Cragle, 908-740-1801orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1789 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: results financial announces merck

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
08.11Parents paying over the odds for baby milk, watchdog warns
08.11The Entertainer axes new shops after Budget tax rise
08.11Hurricane Rafael Graphics
08.11Hurricane Rafael Forecast Discussion Number 19
08.11Hurricane Rafael Wind Speed Probabilities Number 19
08.11Hurricane Rafael Public Advisory Number 19
08.11Summary for Hurricane Rafael (AT3/AL182024)
08.11Harrods boss tells BBC he is 'dreadfully sorry' for Al Fayed abuse
More »